...
首页> 外文期刊>European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery >Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study.
【24h】

Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study.

机译:抑肽酶减少了胸腔手术后的出血和对血液制品的需求:一项随机双盲研究的结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: Bleeding complications have been a major concern in certain thoracic surgery operations, especially decortication and pulmonary resection for inflammatory pulmonary infection. Prevention of plasminogen activation and fibrinolysis by aprotinin administration has been shown to reduce perioperative bleeding during operations associated with high blood consumption. METHODS: Use of blood products (packed red cells, whole blood), chest tube drainage, analgesic requirement, chest tube duration for the patients undergoing major thoracic operations were recorded. In a double blind randomized fashion, patients were assigned to two groups receiving aprotinin (n=51) at a loading dose of 10(6) kallikrein inhibitory units (KIU) followed by an infusion of the same dose during chest closure or receiving placebo (n=52). On a daily basis, red-cell percentages of total fluid from drainage bottles were recorded and using the blood hematocrit level of the patient of the day before, the corrected value for the patient's blood volume equivalent of daily drainage was calculated. RESULTS: There was a significant reduction in perioperative use of donor blood (0.98+/-0.92 vs. 0.45+/-0.32 unit; P=0.0026), and total chest tube drainage (corrected value for the corresponding blood volume) (28.2+/-36.9 vs. 76.9+/-53.3 ml, P=0.0004) (mean+/-standard deviation) in the aprotinin group. However, aprotinin did not reduce postoperative transfusion or decrease in hematocrit level due to thoracic operations. In high transfusion-risk thoracic surgery patients (patients who underwent decortication, pulmonary resection for inflammatory lung disease and chest wall resection), the perioperative transfusion was only 0.50+/-1.08 units in aprotinin group, compared with 1.94+/-0.52 units in control group (P=0.003). Postoperative transfusion was also reduced in aprotinin administrated group (0.53+/-0.56 vs. 1.38+/-0.97 units; P=0.02). The mean total blood loss was decreased to nearly one third of the blood loss of the control group (41+/-28 ml vs. 121+/-68 ml; P=0.001). CONCLUSION: Aprotinin significantly reduced perioperative transfusion requirement and postoperative bleeding during major thoracic operations. Aprotinin decreased perioperative transfusion needs. Moreover, patients who were at risk of greater blood loss during and after certain thoracic operations had a greater potential to benefit from prophylactic perioperative aprotinin treatment.
机译:目的:在某些胸外科手术中,尤其是对于炎症性肺部感染的去皮术和肺切除术,出血并发症一直是主要关注的问题。业已证明,通过抑肽酶给药可预防纤溶酶原激活和纤维蛋白溶解,可减少与高耗血量相关的围手术期出血。方法:记录了进行大胸部手术的患者的血液制品(红细胞,全血),胸腔引流,止痛要求,胸腔持续时间的使用情况。以双盲随机方式,将患者分为两组,分别接受负荷量为10(6)激肽释放酶抑制单位(KIU)的抑肽酶(n = 51),然后在胸腔闭合期间输注相同剂量或接受安慰剂( n = 52)。每天记录引流瓶中总液体的红细胞百分比,并使用前一天患者的血细胞比容水平,计算出患者每日引流血量的校正值。结果:围手术期使用献血者的血量显着减少(0.98 +/- 0.92比0.45 +/- 0.32单位; P = 0.0026)和总胸腔引流(相应血量的校正值)(28.2+抑肽酶组为/-36.9 vs. 76.9 +/- 53.3 ml,P = 0.0004)(平均值+/-标准偏差)。然而,由于胸腔手术,抑肽酶并未减少术后输血或血细胞比容水平的降低。在高风险输注胸腔手术患者中(接受去皮,因炎症性肺疾病行肺切除术和胸壁切除术的患者),抑肽酶组围手术期输血仅为0.50 +/- 1.08单位,相比之下,抑肽酶组为1.94 +/- 0.52单位对照组(P = 0.003)。抑肽酶给药组的术后输血也减少(0.53 +/- 0.56比1.38 +/- 0.97单位; P = 0.02)。平均总失血量减少到对照组失血量的近三分之一(41 +/- 28 ml对121 +/- 68 ml; P = 0.001)。结论:抑肽酶可显着减少大胸部手术期间围手术期的输血需求和术后出血。抑肽酶减少了围手术期的输血需求。此外,在某些胸腔手术期间和之后有更大出血量风险的患者更有可能从围手术期抑肽酶治疗中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号